A retrospective study of 51 patients with recurrent ovarian cancer showed, that pre-treatment TP53 mutational levels in ct-DNA and a decrease of the TP53 MAF >60% between baseline and the second cycle of chemotherapy was associated with increased time to progression [18]. This evidence concerns the gene TP53 and ovarian cancer.